CORRESP 1 filename1.htm

 

September 20, 2019

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re:	Citius Pharmaceuticals, Inc.
	Registration Statement on Form S-1 (Registration No. 333-233759)
	Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), as underwriter for the referenced offering, hereby concurs in the request by Citius Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 p.m. (Eastern Time), or as soon as practicable thereafter, on September 24, 2019, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

	Very truly yours,
	H.C. WAINWRIGHT & CO., LLC
	By:	/s/ Mark W. Viklund
		Name: Mark W. Viklund Title: Chief Executive Officer